Treatment Efficacy for Drug Abuse and AIDS Prevention - 2

The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cocaine-Related Disorders Chemically-Induced Disorders Heroin Dependence Mental Disorders Narcotic-Related Disorders Opioid-Related Disorders Substance-Related Disorders

Age range

26 year–41 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

McLean Hospital, Dept. of Psychiatry

Belmont, Massachusetts, 2178, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Please contact site for information.

Treatment and study plan

buprenorphine

Drug

Sponsors and collaborators

Lead sponsor

National Institute on Drug Abuse (NIDA)

Nih

Collaborators

Mclean Hospital

Registry information

Official study title

Treatment Efficacy for Drug Abuse and AIDS Prevention

Important dates

Study start: 1989
Primary completion: 1996
Study completion: 1996
First posted: Sep 21, 1999
Registry last updated: Jan 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed